BACKGROUND: A plethora of agents is in early stages of development for colorectal cancer (CRC), including those that target the insulin-like growth factor I receptor (IGFIR) pathway. In the current environment of numerous cancer targets, it is imperative that patient selection strategies be developed with the intent of preliminary testing in the latter stages of phase I trials. The goal of this study was to develop and characterize predictive biomarkers for an IGFIR tyrosine kinase inhibitor, OSI-906, that could be applied in CRC-specific studies of this agent. METHODS: Twenty-seven CRC cell lines were exposed to OSI-906 and classified according to IC(50) value as sensitive (<or=1.5 micromol/L) or resistant (>5 micromol/L). Cell lines were subjected to immunoblotting and immunohistochemistry for effector proteins, IGFIR copy number by fluorescence in situ hybridization, KRAS/BRAF/phosphoinositide 3-kinase mutation status, and baseline gene array analysis. The most sensitive and resistant cell lines were used for gene array and pathway analyses, along with shRNA knockdown of highly ranked genes. The resulting integrated genomic classifier was then tested against eight human CRC explants in vivo. RESULTS: Baseline gene array data from cell lines and xenografts were used to develop a k-top scoring pair (k-TSP) classifier, which, in combination with IGFIR fluorescence in situ hybridization and KRAS mutational status, was able to predict with 100% accuracy a test set of patient-derived CRC xenografts. CONCLUSIONS: These results indicate that an integrated approach to the development of individualized therapy is feasible and should be applied early in the development of novel agents, ideally in conjunction with late-stage phase I trials. (c) 2010 AACR.
BACKGROUND: A plethora of agents is in early stages of development for colorectal cancer (CRC), including those that target the insulin-like growth factor I receptor (IGFIR) pathway. In the current environment of numerous cancer targets, it is imperative that patient selection strategies be developed with the intent of preliminary testing in the latter stages of phase I trials. The goal of this study was to develop and characterize predictive biomarkers for an IGFIR tyrosine kinase inhibitor, OSI-906, that could be applied in CRC-specific studies of this agent. METHODS: Twenty-seven CRC cell lines were exposed to OSI-906 and classified according to IC(50) value as sensitive (<or=1.5 micromol/L) or resistant (>5 micromol/L). Cell lines were subjected to immunoblotting and immunohistochemistry for effector proteins, IGFIR copy number by fluorescence in situ hybridization, KRAS/BRAF/phosphoinositide 3-kinase mutation status, and baseline gene array analysis. The most sensitive and resistant cell lines were used for gene array and pathway analyses, along with shRNA knockdown of highly ranked genes. The resulting integrated genomic classifier was then tested against eight human CRC explants in vivo. RESULTS: Baseline gene array data from cell lines and xenografts were used to develop a k-top scoring pair (k-TSP) classifier, which, in combination with IGFIR fluorescence in situ hybridization and KRAS mutational status, was able to predict with 100% accuracy a test set of patient-derived CRC xenografts. CONCLUSIONS: These results indicate that an integrated approach to the development of individualized therapy is feasible and should be applied early in the development of novel agents, ideally in conjunction with late-stage phase I trials. (c) 2010 AACR.
Authors: Matthias M Weber; Christian Fottner; Sun Bin Liu; M Christina Jung; Dieter Engelhardt; Gustavo B Baretton Journal: Cancer Date: 2002-11-15 Impact factor: 6.860
Authors: F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri Journal: Mol Cell Biol Date: 1999-05 Impact factor: 4.272
Authors: Ki Young Chung; Jinru Shia; Nancy E Kemeny; Manish Shah; Gary K Schwartz; Archie Tse; Audrey Hamilton; Dorothy Pan; Deborah Schrag; Lawrence Schwartz; David S Klimstra; Daniel Fridman; David P Kelsen; Leonard B Saltz Journal: J Clin Oncol Date: 2005-01-27 Impact factor: 44.544
Authors: P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd Journal: J Natl Cancer Inst Date: 1990-07-04 Impact factor: 13.506
Authors: Marina Pajic; Christopher J Scarlett; David K Chang; Robert L Sutherland; Andrew V Biankin Journal: Hum Genet Date: 2011-04-23 Impact factor: 4.132
Authors: Jennifer R Diamond; Ravi Salgia; Marileila Varella-Garcia; Rajani Kanteti; Patricia M LoRusso; Jeffrey W Clark; Ling-Guo Xu; Keith Wilner; S Gail Eckhardt; Keith A Ching; Maruja E Lira; Eric F P M Schoenmakers; James G Christensen; D Ross Camidge Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Amit Khatri; Richard C Brundage; Jessica M Hull; Brent W Williams; Douglas Yee; Mark N Kirstein Journal: AAPS J Date: 2011-11-19 Impact factor: 4.009
Authors: John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt Journal: Nat Rev Clin Oncol Date: 2012-04-17 Impact factor: 66.675
Authors: Sara A Flanigan; Todd M Pitts; Timothy P Newton; Gillian N Kulikowski; Aik Choon Tan; Martine C McManus; Anna Spreafico; Maria I Kachaeva; Heather M Selby; John J Tentler; S Gail Eckhardt; Stephen Leong Journal: Clin Cancer Res Date: 2013-09-17 Impact factor: 12.531